P2 purinergic receptor expression and function in tumor-related immune cells.
Immune cells
Macrophages
Neutrophils
P2 purinergic receptor
T-cells
Tumor microenvironment
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
10 Oct 2024
10 Oct 2024
Historique:
received:
17
04
2024
accepted:
27
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
aheadofprint
Résumé
P2 purinergic receptor expression is dysregulated in multiple cancer subtypes and is associated with worse outcomes. Studies identify roles for P2 purinergic receptors in tumor cells that drive disease aggressiveness. There is also sufficient evidence that P2 purinergic receptor expression within the tumor microenvironment (TME) is critical for disease initiation and progression. Immune cells constitute a significant component of the TME and display both tumorigenic and anti-tumorigenic potential. Studies pre-dating the investigation of P2 purinergic receptors in cancer identify P2 receptor expression on multiple immune cells including macrophages, neutrophils, T-cells, and dendritic cells; all of which are implicated in tumor initiation, tumor promotion, or response to treatment. Herein, we discuss P2 purinergic receptor expression and function in tumor-related immune cells. We provide a rationale for further investigations of P2 purinergic receptors within the TME to better define the mechanistic pathways of inflammation-mediate tumorigenesis and explore P2 purinergic receptors as potential targets for novel immunotherapeutic approaches.
Identifiants
pubmed: 39387963
doi: 10.1007/s11302-024-10054-7
pii: 10.1007/s11302-024-10054-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu S-G, Huang C (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6:162
pubmed: 33907179
pmcid: 8079716
doi: 10.1038/s41392-021-00553-z
Burnstock G (2018) Purine and purinergic receptors. Brain Neurosci Adv 2:2398212818817494
pubmed: 32166165
pmcid: 7058212
doi: 10.1177/2398212818817494
Sarikaya E (2019) Functions of purinergic receptors. In Receptors P1 and P2 as targets for drug therapy in humans, IntechOpen: 2019
da Silva Ferreira NC, Alves LA, Soares-Bezerra RJ (2019) Potential therapeutic applications of P2 receptor antagonists: from bench to clinical trials. Curr Drug Targets 20:919–937
pubmed: 30760187
doi: 10.2174/1389450120666190213095923
Maynard JP, Sfanos KS (2022) P2 purinergic receptor dysregulation in urologic disease. Purinergic Signal 18:267–287
pubmed: 35687210
pmcid: 9184359
doi: 10.1007/s11302-022-09875-1
Draganov D, Han Z, Rana A, Bennett N, Irvine DJ, Lee PP (2021) Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer 7:22
pubmed: 33654071
pmcid: 7925581
doi: 10.1038/s41523-021-00229-5
Douguet L, dit Hreich SJ, Benzaquen J, Seguin L, Juhel T, Dezitter X, Duranton C, Ryffel B, Kanellopoulos J, Delarasse C (2021) A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Comm 12:653
doi: 10.1038/s41467-021-20912-2
Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9:1612
pubmed: 32635260
pmcid: 7407645
doi: 10.3390/cells9071612
Zhu X, Li Q, Song W, Peng X, Zhao R (2021) P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med 99:349–358
pubmed: 33486566
doi: 10.1007/s00109-021-02041-x
Xia J, Yu X, Tang L, Li G, He T (2015) P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep 34:103–110
pubmed: 25976617
doi: 10.3892/or.2015.3979
Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa RY, Peiffer LB (2022) P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. J Pathol 256:149–163
pubmed: 34652816
doi: 10.1002/path.5815
Qiao C, Tang Y, Li Q, Zhu X, Peng X, Zhao R (2022) ATP-gated P2X7 receptor as a potential target for prostate cancer. Hum Cell 35:1346–1354
pubmed: 35657562
doi: 10.1007/s13577-022-00729-x
Li Q, Zhu X, Song W, Peng X, Zhao R (2020) The P2X7 purinergic receptor: a potential therapeutic target for lung cancer. J Cancer Res Clin Oncol 146:2731–2741
pubmed: 32892231
doi: 10.1007/s00432-020-03379-4
Placet M, Arguin G, Molle CM, Babeu J-P, Jones C, Carrier JC, Robaye B, Geha S, Boudreau F, Gendron F-P (2018) The G protein-coupled P2Y6 receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis 1864:1539–1551
Hu L-P, Zhang X-X, Jiang S-H, Tao L-Y, Li Q, Zhu L-L, Yang M-W, Huo Y-M, Jiang Y-S, Tian G-A (2019) Targeting purinergic receptor P2Y2 prevents the growth of pancreatic ductal adenocarcinoma by inhibiting cancer cell glycolysis. Clin Cancer Res 25:1318–1330
pubmed: 30420446
doi: 10.1158/1078-0432.CCR-18-2297
Maynard JP, Lee J-S, Sohn BH, Yu X, Lopez-Terrada D, Finegold MJ, Goss JA, Thevananther S (2015) P2X3 purinergic receptor overexpression is associated with poor recurrence-free survival in hepatocellular carcinoma patients. Oncotarget 6:41162
pubmed: 26517690
pmcid: 4747397
doi: 10.18632/oncotarget.6240
Liu Z, Liu Y, Xu L, An H, Chang Y, Yang Y, Zhang W, Xu J (2015) P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma. Cancer Sci 106:1224–1231
pubmed: 26179886
pmcid: 4582993
doi: 10.1111/cas.12736
Ledderose S, Rodler S, Eismann L, Ledderose G, Rudelius M, Junger WG, Ledderose C (2023) P2X1 and P2X7 receptor overexpression is a negative predictor of survival in muscle-invasive bladder cancer. Cancers 15:2321
pubmed: 37190249
pmcid: 10136747
doi: 10.3390/cancers15082321
Idzko M, Ferrari D, Eltzschig HK (2014) Nucleotide signalling during inflammation. Nature 509:310–317
pubmed: 24828189
pmcid: 4222675
doi: 10.1038/nature13085
White N, Burnstock G (2006) P2 receptors and cancer. Trends Pharmacol Sci 27:211–217
pubmed: 16530853
doi: 10.1016/j.tips.2006.02.004
Mühleder S, Fuchs C, Basílio J, Szwarc D, Pill K, Labuda K, Slezak P, Siehs C, Pröll J, Priglinger E (2020) Purinergic P2Y 2 receptors modulate endothelial sprouting. Cell Mol Life Sci 77:885–901
pubmed: 31278420
doi: 10.1007/s00018-019-03213-2
Rayah A, Kanellopoulos JM, Di Virgilio F (2012) P2 receptors and immunity. Microbes Infect 14:1254–1262
pubmed: 22909902
pmcid: 3514633
doi: 10.1016/j.micinf.2012.07.006
Cao Y, Chen E, Wang X, Song J, Zhang H, Chen X (2023) An emerging master inducer and regulator for epithelial-mesenchymal transition and tumor metastasis: extracellular and intracellular ATP and its molecular functions and therapeutic potential. Cancer Cell Int 23:1–16
doi: 10.1186/s12935-023-02859-0
Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921–R925
pubmed: 32810447
pmcid: 8194051
doi: 10.1016/j.cub.2020.06.081
Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E (2018) Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer 18:601–618
pubmed: 30006588
doi: 10.1038/s41568-018-0037-0
de Visser KE, Joyce JA (2023) The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell 41:374–403
pubmed: 36917948
doi: 10.1016/j.ccell.2023.02.016
Denk D, Greten FR (2022) Inflammation: the incubator of the tumor microenvironment. Trends Cancer 8:901
pubmed: 35907753
doi: 10.1016/j.trecan.2022.07.002
Canli Ö, Nicolas AM, Gupta J, Finkelmeier F, Goncharova O, Pesic M, Neumann T, Horst D, Löwer M, Sahin U (2017) Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell 32(869–883):e865
Jacob F, Novo CP, Bachert C, Van Crombruggen K (2013) Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:285–306
pubmed: 23404828
pmcid: 3757148
doi: 10.1007/s11302-013-9357-4
Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16:177–192
pubmed: 26922909
doi: 10.1038/nri.2016.4
Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282–286
pubmed: 19741708
pmcid: 2851546
doi: 10.1038/nature08296
Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35:5931–5941
pubmed: 27086930
pmcid: 5119456
doi: 10.1038/onc.2016.104
Murao A, Aziz M, Wang H, Brenner M, Wang P (2021) Release mechanisms of major DAMPs. Apoptosis 26:152–162
pubmed: 33713214
pmcid: 8016797
doi: 10.1007/s10495-021-01663-3
Marques-da-Silva C, Burnstock G, Ojcius DM, Coutinho-Silva R (2011) Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages. Immunobiology 216:1–11
pubmed: 20471713
doi: 10.1016/j.imbio.2010.03.010
Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B, Posmantur R (2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease. J Biol Chem 278:13309–13317
pubmed: 12551918
doi: 10.1074/jbc.M209478200
Gruenbacher G, Gander H, Dobler G, Rahm A, Klaver D, Thurnher M (2021) The human G protein-coupled ATP receptor P2Y11 is a target for anti-inflammatory strategies. Br J Pharmacol 178:1541–1555
pubmed: 33463722
doi: 10.1111/bph.15379
Curet MA, Watters JJ (2018) P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures. J Neurooncol 137:23–31
pubmed: 29189936
doi: 10.1007/s11060-017-2700-9
Pavlović N, Kopsida M, Gerwins P, Heindryckx F (2020) Inhibiting P2Y12 in macrophages induces endoplasmic reticulum stress and promotes an anti-tumoral phenotype. Int J Mol Sci 21:8177
pubmed: 33142937
pmcid: 7672568
doi: 10.3390/ijms21218177
Kloss L, Dollt C, Schledzewski K et al (2019) ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. Cell Death Dis 10:760
pubmed: 31591378
pmcid: 6779894
doi: 10.1038/s41419-019-2010-6
Chen S, Feng W, Yang X, Yang W, Ru Y, Liao J, Wang L, Lin Y, Ren Q, Zheng G (2014) Functional expression of P2X family receptors in macrophages is affected by microenvironment in mouse T cell acute lymphoblastic leukemia. Biochem Biophys Res Commun 446:1002–1009
pubmed: 24661878
doi: 10.1016/j.bbrc.2014.03.048
Qin J, Zhang X, Tan B, Zhang S, Yin C, Xue Q, Zhang Z, Ren H, Chen J, Liu M (2020) Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer. Cancer Immunol Res 8:1426–1439
pubmed: 32933967
doi: 10.1158/2326-6066.CIR-20-0123
Guo L-H, Trautmann K, Schluesener HJ (2004) Expression of P2X4 receptor in rat C6 glioma by tumor-associated macrophages and activated microglia. J Neuroimmunol 152:67–72
pubmed: 15223238
doi: 10.1016/j.jneuroim.2004.04.005
Nylund G, Hultman L, Nordgren S, Delbro D (2007) P2Y2-and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton Autacoid Pharmacol 27:79–84
pubmed: 17391276
doi: 10.1111/j.1474-8673.2007.00389.x
Wang X, Hu L-P, Qin W-T, Yang Q, Chen D-Y, Li Q, Zhou K-X, Huang P-Q, Xu C-J, Li J (2021) Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun 12:174
pubmed: 33420030
pmcid: 7794439
doi: 10.1038/s41467-020-20447-y
Yamamoto S, Matsuo K, Sakai S, Mishima I, Hara Y, Oiso N, Kawada A, Yoshie O, Nakayama T (2021) P2X receptor agonist enhances tumor-specific CTL responses through CD70+ DC-mediated Th17 induction. Int Immunol 33:49–55
pubmed: 33027512
doi: 10.1093/intimm/dxaa068
Romagnani A, Rottoli E, Mazza EMC et al (2020) P2X7 receptor activity limits accumulation of T cells within tumors. Cancer Res 80:3906–3919
pubmed: 32699136
pmcid: 7611351
doi: 10.1158/0008-5472.CAN-19-3807
Baroja-Mazo A, Peñín-Franch A, Lucas-Ruiz F, de Torre-Minguela C, Alarcón-Vila C, Hernández-Caselles T, Pelegrín P (2023) P2X7 receptor activation impairs antitumour activity of natural killer cells. Br J Pharmacol 180:111–128
pubmed: 36098250
doi: 10.1111/bph.15951
Coutinho-Silva R, Savio LEB (2021) Purinergic signalling in host innate immune defence against intracellular pathogens. Biochem Pharmacol 187:114405
pubmed: 33406411
doi: 10.1016/j.bcp.2021.114405
Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15:11–24
pubmed: 29089606
doi: 10.1038/nrurol.2017.167
Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S (2021) Innate immune cells in the tumor microenvironment. Cancer Cell 39:725–729
pubmed: 34129817
doi: 10.1016/j.ccell.2021.05.016
Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I (2023) M1/M2 macrophages and their overlaps - myth or reality? Clin Sci (Lond) 137:1067–1093. https://doi.org/10.1042/cs20220531
doi: 10.1042/cs20220531
pubmed: 37530555
Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X (2020) Tumor-associated macrophages: recent insights and therapies. Front Oncol 10:188
pubmed: 32161718
pmcid: 7052362
doi: 10.3389/fonc.2020.00188
Hao N-B, Lü M-H, Fan Y-H, Cao Y-L, Zhang Z-R, Yang S-M (2012) Macrophages in tumor microenvironments and the progression of tumors. J Immunol Res 2012:1
Boutilier AJ, Elsawa SF (2021) Macrophage polarization states in the tumor microenvironment. Int J Mol Sci 22. https://doi.org/10.3390/ijms22136995
Joo YN, Jin H, Eun SY, Park SW, Chang KC, Kim HJ (2014) P2Y2R activation by nucleotides released from the highly metastatic breast cancer cell contributes to pre-metastatic niche formation by mediating lysyl oxidase secretion, collagen crosslinking, and monocyte recruitment. Oncotarget 5:9322
pubmed: 25238333
pmcid: 4253437
doi: 10.18632/oncotarget.2427
Jin H, Eun SY, Lee JS, Park SW, Lee JH, Chang KC, Kim HJ (2014) P2Y2receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. Breast Cancer Res 16:1–14
doi: 10.1186/bcr3694
Johansson N, Ahonen M, Kähäri V-M (2000) Matrix metalloproteinases in tumor invasion. Cell Mol life Sci CMLS 57:5–15
pubmed: 10949577
doi: 10.1007/s000180050495
Wang J, Shi W, Miao Y, Gan J, Guan Q, Ran J (2021) Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13. Bioengineered 12:6286–6304
pubmed: 34494914
pmcid: 8806861
doi: 10.1080/21655979.2021.1971029
Yu L, Cao S, Li J, Han B, Zhong H, Zhong R (2021) Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Int Immunopharmacol 98:107734
pubmed: 34175738
doi: 10.1016/j.intimp.2021.107734
Fan T, Zhu M, Wang L, Liu Y, Tian H, Zheng Y, Tan F, Sun N, Li C, He J (2021) Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma. Aging (Albany NY) 13:2397
doi: 10.18632/aging.202269
Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Can Res 75:635–644
doi: 10.1158/0008-5472.CAN-14-1259
Casey M, Segawa K, Law SC, Sabdia MB, Nowlan B, Salik B, Lee C, Winterford C, Pearson S, Madore J (2023) Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma. Leukemia 37:379–387
pubmed: 36539557
doi: 10.1038/s41375-022-01794-9
Li X-Y, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A (2019) Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity. Cancer Discov 9:1754–1773
pubmed: 31699796
pmcid: 6891207
doi: 10.1158/2159-8290.CD-19-0541
Zhou Y, Fei M, Zhang G, Liang W-C, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H (2020) Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity 52(357–373):e359
Fang KM, Wang YL, Huang MC, Sun SH, Cheng H, Tzeng SF (2011) Expression of macrophage inflammatory protein-1α and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X7 receptor. J Neurosci Res 89:199–211
pubmed: 21162127
doi: 10.1002/jnr.22538
Gruenbacher G, Gander H, Rahm A, Dobler G, Drasche A, Troppmair J, Nussbaumer W, Thurnher M (1870) The human G protein-coupled ATP receptor P2Y11 is associated with IL-10 driven macrophage differentiation. Front Immunol 2019:10
Klaver D, Gander H, Dobler G, Rahm A, Thurnher M (2022) The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses. Cell Mol Life Sci 79:519
pubmed: 36107259
doi: 10.1007/s00018-022-04548-z
Li Q, Xu L, Li Y, Yang R, Qiao Q, Wang Y, Wang L, Guo Y, Guo C (2021) P2RY14 is a potential biomarker of tumor microenvironment immunomodulation and favorable prognosis in patients with head and neck cancer. Front Genet 12:670746
pubmed: 34306014
pmcid: 8297391
doi: 10.3389/fgene.2021.670746
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat Med 15:1170–1178
pubmed: 19767732
doi: 10.1038/nm.2028
Bles N, Di Pietrantonio L, Boeynaems J-M, Communi D (2010) ATP confers tumorigenic properties to dendritic cells by inducing amphiregulin secretion. Blood J Am Soc Hematol 116:3219–3226
Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y (2018) Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol 19:1236–1247
pubmed: 30323345
pmcid: 6195445
doi: 10.1038/s41590-018-0229-5
Li Z, Gao Y, He C, Wei H, Zhang J, Zhang H, Hu L, Jiang W (2021) Purinergic receptor P2Y6 is a negative regulator of NK cell maturation and function. J Immunol 207:1555–1565
pubmed: 34426542
doi: 10.4049/jimmunol.2000750
Ledderose C, Bromberger S, Slubowski CJ, Sueyoshi K, Aytan D, Shen Y, Junger WG (2020) The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes. Sci Signal 13:eaba3300
pubmed: 32994212
pmcid: 8826773
doi: 10.1126/scisignal.aba3300
Trabanelli S, Očadlíková D, Gulinelli S, Curti A, Salvestrini V, de Paula Vieira R, Idzko M, Di Virgilio F, Ferrari D, Lemoli RM (2012) Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol 189:1303–1310
pubmed: 22753942
doi: 10.4049/jimmunol.1103800
De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo MP, Di Virgilio F, Adinolfi E (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38:3636–3650
pubmed: 30655604
pmcid: 6756114
doi: 10.1038/s41388-019-0684-y
Zhu C, Kros JM, van der Weiden M, Zheng P, Cheng C, Mustafa DA (2017) Expression site of P2RY12 in residential microglial cells in astrocytomas correlates with M1 and M2 marker expression and tumor grade. Acta Neuropathol Commun 5:1–12
doi: 10.1186/s40478-016-0405-5
Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741
pubmed: 18980965
doi: 10.1158/1078-0432.CCR-07-4843
Kadomoto S, Izumi K, Mizokami A (2020) The CCL20-CCR6 axis in cancer progression. Int J Mol Sci 21:5186
pubmed: 32707869
pmcid: 7432448
doi: 10.3390/ijms21155186
Yu Q, Lou X-M, He Y (2015) Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway. PLoS ONE 10:e0120855
pubmed: 25768730
pmcid: 4359139
doi: 10.1371/journal.pone.0120855
Ye J, Livergood RS, Peng G (2013) The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 182:10–20
pubmed: 23159950
pmcid: 3532708
doi: 10.1016/j.ajpath.2012.08.041
Chen K-J, Lin S-Z, Zhou L, Xie H-Y, Zhou W-H, Taki-Eldin A, Zheng S-S (2011) Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE 6:e24671
pubmed: 21935436
pmcid: 3173477
doi: 10.1371/journal.pone.0024671
Bidula S, Dhuna K, Helliwell R, Stokes L (2019) Positive allosteric modulation of P2X7 promotes apoptotic cell death over lytic cell death responses in macrophages. Cell Death Dis 10:882
pubmed: 31767863
pmcid: 6877589
doi: 10.1038/s41419-019-2110-3
Yang C, Shi S, Su Y, Tong JS, Li L (2020) P2X7R promotes angiogenesis and tumour-associated macrophage recruitment by regulating the NF-κB signalling pathway in colorectal cancer cells. J Cell Mol Med 24:10830–10841
pubmed: 32735377
pmcid: 7521273
doi: 10.1111/jcmm.15708
Dwyer AR, Greenland EL, Pixley FJ (2017) Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers 9:68
pubmed: 28629162
pmcid: 5483887
doi: 10.3390/cancers9060068
Avila MA, Berasain C (2019) Targeting CCL2/CCR2 in tumor-infiltrating macrophages: a tool emerging out of the box against hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol 7:293–294
pubmed: 30529279
doi: 10.1016/j.jcmgh.2018.11.002
Aricò E, Castiello L, Capone I, Gabriele L, Belardelli F (1943) Type I interferons and cancer: an evolving story demanding novel clinical applications. Cancers 2019:11
Takenaka MC, Robson S, Quintana FJ (2016) Regulation of the T cell response by CD39. Trends Immunol 37:427–439
pubmed: 27236363
pmcid: 5215082
doi: 10.1016/j.it.2016.04.009
Yoshimura T (2018) The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol 15:335–345
pubmed: 29375123
pmcid: 6052833
doi: 10.1038/cmi.2017.135
Bhavsar I, Miller CS, Al-Sabbagh M (2015) Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. Gen Methods Biomarker Res App 2015:223
Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F, Oxidized ATP (1993) An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biological Chem 268:8199–8203
doi: 10.1016/S0021-9258(18)53082-9
Kolaczkowska E, Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13:159–175
pubmed: 23435331
doi: 10.1038/nri3399
Raftopoulou S, Valadez-Cosmes P, Mihalic ZN, Schicho R, Kargl J (2022) Tumor-mediated neutrophil polarization and therapeutic implications. Int J Mol Sci 23:3218
pubmed: 35328639
pmcid: 8951452
doi: 10.3390/ijms23063218
Wang X, Chen D (2018) Purinergic regulation of neutrophil function. Front Immunol 9:399
pubmed: 29545806
pmcid: 5837999
doi: 10.3389/fimmu.2018.00399
Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33:949–955. https://doi.org/10.1093/carcin/bgs123
doi: 10.1093/carcin/bgs123
pubmed: 22425643
Raskov H, Orhan A, Gaggar S, Gögenur I (2022) Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis 11:22
pubmed: 35504900
pmcid: 9065109
doi: 10.1038/s41389-022-00398-3
Yan M, Zheng M, Niu R, Yang X, Tian S, Fan L, Li Y, Zhang S (2022) Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications. Frontiers Cell Dev Biol 10:938289
doi: 10.3389/fcell.2022.938289
Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A (2020) Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer 20:485–503
pubmed: 32694624
doi: 10.1038/s41568-020-0281-y
Jablonska J, Wu CF, Andzinski L, Leschner S, Weiss S (2014) CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β. Int J Cancer 134:1346–1358
pubmed: 24154944
doi: 10.1002/ijc.28551
Wu Y, Wang S, Farooq SM, Castelvetere MP, Hou Y, Gao J-L, Navarro JV, Oupicky D, Sun F, Li C (2012) A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. J Biol Chem 287:5744–5755
pubmed: 22203670
doi: 10.1074/jbc.M111.315762
Patel CH, Leone RD, Horton MR, Powell JD (2019) Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discovery 18:669–688
pubmed: 31363227
doi: 10.1038/s41573-019-0032-5
Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22
pubmed: 22136168
doi: 10.1146/annurev-immunol-100311-102839
Merad M, Sathe P, Helft J, Miller J, Mortha A (2013) The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 31:563–604
pubmed: 23516985
doi: 10.1146/annurev-immunol-020711-074950
Cabeza-Cabrerizo, M.; Cardoso, A.; Minutti, C.M.; Pereira da Costa, M.; Reis e Sousa, C. Dendritic cells revisited. Annual review of immunology 2021, 39, 131–166.
Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. In Proceed Sem Immunol 52:101481
doi: 10.1016/j.smim.2021.101481
Mutini C, Falzoni S, Ferrari D, Chiozzi P, Morelli A, Baricordi OR, Collo G, Ricciardi-Castagnoli P, Di Virgilio F (1999) Mouse dendritic cells express the P2X7 purinergic receptor: characterization and possible participation in antigen presentation. J Immunol 163:1958–1965
pubmed: 10438932
doi: 10.4049/jimmunol.163.4.1958
Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31:787–798
pubmed: 19879162
pmcid: 2787786
doi: 10.1016/j.immuni.2009.09.014
Ankathatti Munegowda M, Deng Y, Mulligan SJ, Xiang J (2011) Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunity. Cancer Immunol Immunother 60:1473–1484
pubmed: 21660450
pmcid: 11028972
doi: 10.1007/s00262-011-1054-y
Bulanova E, Bulfone-Paus S (2010) P2 receptor-mediated signaling in mast cell biology. Purinergic Signalling 6:3–17
pubmed: 19921464
doi: 10.1007/s11302-009-9173-z
Paalme V, Rump A, Mädo K, Teras M, Truumees B, Aitai H, Ratas K, Bourge M, Chiang C-S, Ghalali A (2019) Human peripheral blood eosinophils express high levels of the purinergic receptor P2X4. Front Immunol 10:2074
pubmed: 31552031
pmcid: 6746186
doi: 10.3389/fimmu.2019.02074
Ferrari D, la Sala A, Panther E, Norgauer J, Di Virgilio F, Idzko M (2006) Activation of human eosinophils via P2 receptors: novel findings and future perspectives. J Leukoc Biol 79:7–15
pubmed: 16244111
doi: 10.1189/jlb.0505286
Nakano M, Ito K, Yuno T, Soma N, Aburakawa S, Kasai K, Nakamura T, Takami H (2017) UDP/P2Y6 receptor signaling regulates IgE-dependent degranulation in human basophils. Allergol Int 66:574–580
pubmed: 28318884
doi: 10.1016/j.alit.2017.02.014
Marone G, Schroeder JT, Mattei F, Loffredo S, Gambardella AR, Poto R, De Paulis A, Schiavoni G, Varricchi G (2020) Is there a role for basophils in cancer? Front Immunol 11:2103
pubmed: 33013885
pmcid: 7505934
doi: 10.3389/fimmu.2020.02103
Alberto AVP, da Silva Ferreira NC, Bonavita AGC, Nihei OK, de Farias FP, da Cunha Bisaggio R, de Albuquerque C, Savino W, Coutinho-Silva R, Persechini PM (2022) Physiologic roles of P2 receptors in leukocytes. J Leukocyte Biol 112:983–1012
pubmed: 35837975
doi: 10.1002/JLB.2RU0421-226RR
Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235–271
pubmed: 21219185
doi: 10.1146/annurev-immunol-031210-101324
Schiavoni G, Gabriele L, Mattei F (2013) The tumor microenvironment: a pitch for multiple players. Front Oncol 3:45261
doi: 10.3389/fonc.2013.00090
Gajewski TF, Schreiber H, Fu Y-X (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022
pubmed: 24048123
pmcid: 4118725
doi: 10.1038/ni.2703
Huang Y, Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Hunborg P, Varvares MA, Hoft DF, Hsueh EC (2015) CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget 6:17462
pubmed: 25968569
pmcid: 4627321
doi: 10.18632/oncotarget.3958
Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666
pubmed: 16371631
doi: 10.1056/NEJMoa051424
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1:1323–1343
pubmed: 23243596
pmcid: 3518505
doi: 10.4161/onci.22009
Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metas 26:311–327
doi: 10.1007/s10585-008-9196-9
Feng L-L, Cai Y-Q, Zhu M-C, Xing L-J, Wang X (2020) The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 20:1–11
doi: 10.1186/s12935-020-01195-x
Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J (2019) Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett 205:31–39
pubmed: 29758241
doi: 10.1016/j.imlet.2018.05.001
Wanhainen KM, Peng C, Zhou MH, Macedo BDG, O’Flanagan S, Yang T, Kelekar A, Burbach BJ, Borges da Silva H, Jameson SC (2022) P2RX7 enhances tumor control by CD8+ T cells in adoptive cell therapy. Cancer Immunol Res 10:871–884
pubmed: 35588154
pmcid: 9250641
doi: 10.1158/2326-6066.CIR-21-0691
Stark R, Wesselink TH, Behr FM, Kragten NA, Arens R, Koch-Nolte F, van Gisbergen KP, van Lier RA (2018) T RM maintenance is regulated by tissue damage via P2RX7. Sci Immunol 3:eaau1022
pubmed: 30552101
doi: 10.1126/sciimmunol.aau1022
Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J (2015) Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6:13835
pubmed: 26079948
pmcid: 4537053
doi: 10.18632/oncotarget.3453
Cózar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E (2021) Tumor-infiltrating natural killer cells Cancer discovery 11:34–44
pubmed: 33277307
Russick J, Torset C, Hemery E, Cremer I (2020) NK cells in the tumor microenvironment: prognostic and theranostic impact. Recent advances and trends. Proceed Sem Immunol 48:101407
doi: 10.1016/j.smim.2020.101407
Yang Y, Chen L, Zheng B, Zhou S (2023) Metabolic hallmarks of natural killer cells in the tumor microenvironment and implications in cancer immunotherapy. Oncogene 42:1–10
pubmed: 36473909
doi: 10.1038/s41388-022-02562-w
Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL (2005) Platelets and fibrin (ogen) increase metastatic potential by impeding natural killer cell–mediated elimination of tumor cells. Blood 105:178–185
pubmed: 15367435
doi: 10.1182/blood-2004-06-2272
Contursi A, Sacco A, Grande R, Dovizio M, Patrignani P (2017) Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell Mol Life Sci 74:3491–3507
pubmed: 28488110
pmcid: 11107532
doi: 10.1007/s00018-017-2536-7
Gareau AJ, Brien C, Gebremeskel S, Liwski RS, Johnston B, Bezuhly M (2018) Ticagrelor inhibits platelet–tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metas 35:25–35
doi: 10.1007/s10585-018-9874-1
Dersh D, Hollý J, Yewdell JW (2021) A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol 21:116–128
pubmed: 32820267
doi: 10.1038/s41577-020-0390-6
Kursunel MA, Esendagli G (2016) The untold story of IFN-γ in cancer biology. Cytokine Growth Factor Rev 31:73–81
pubmed: 27502919
doi: 10.1016/j.cytogfr.2016.07.005
Lee DH, Park KS, Kong ID, Kim JW, Han BG (2006) Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines. BMC Immunol 7:1–11
doi: 10.1186/1471-2172-7-22